• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

103例先天性甲状腺功能减退症患儿在甲状腺激素替代治疗前及治疗期间的头围、身高、骨龄和体重。

Head circumference, height, bone age and weight in 103 children with congenital hypothyroidism before and during thyroid hormone replacement.

作者信息

Bucher H, Prader A, Illig R

出版信息

Helv Paediatr Acta. 1985 Sep;40(4):305-16.

PMID:4077564
Abstract

Head circumference, height, bone age and weight were studied in 103 children with congenital hypothyroidism before and up to 8 years of thyroid replacement therapy. The patients were divided into 4 groups according to the age at start of treatment: group I (diagnosed by neonatal screening): less than 2 weeks (n = 55); group II: 1-3 months (n = 7); group III: 4-12 months (n = 15); group IV: greater than 1 year of age (n = 26). Before treatment, group I showed a head circumference significantly larger than normal and a delay in bone maturation in the presence of normal length and weight. In the other groups length as well as bone age were significantly lower than normal, head circumference, in contrast, was normal (groups II and III) or even increased (group IV). During therapy, head circumference and bone age of group I became normal as were length and weight from the beginning. In the other groups, therapy led to a further increase of head size resulting in a mean head circumference significantly larger than normal during 8 years of observation in group IV. There was a catch-up of height, bone age and weight in groups II, III and IV; mean height of late treated children (group IV), however, remained significantly lower than normal even after 8 years of therapy. - Our study shows that congenital hypothyroidism is associated with increased head circumference, either absolutely or in relation to stature. Thyroid hormone therapy resulted in a normalization of head growth when treatment was initiated early, and in a further increase when treatment was started late. There was a catch-up of height, bone age and weight; complete normalization, however, occurred only in those children treated before one year of age.

摘要

对103例先天性甲状腺功能减退症患儿在甲状腺替代治疗前及治疗长达8年期间的头围、身高、骨龄和体重进行了研究。根据开始治疗时的年龄将患者分为4组:I组(通过新生儿筛查诊断):小于2周(n = 55);II组:1 - 3个月(n = 7);III组:4 - 12个月(n = 15);IV组:大于1岁(n = 26)。治疗前,I组头围明显大于正常,在身长和体重正常的情况下骨成熟延迟。在其他组中,身长和骨龄明显低于正常,相比之下,头围正常(II组和III组)或甚至增加(IV组)。治疗期间,I组的头围和骨龄恢复正常,身长和体重从一开始就正常。在其他组中,治疗导致头围进一步增大,在IV组8年的观察期内平均头围明显大于正常。II组、III组和IV组的身高、骨龄和体重出现追赶生长;然而,即使经过8年治疗,治疗较晚的儿童(IV组)的平均身高仍明显低于正常。——我们的研究表明,先天性甲状腺功能减退症与头围增大有关,无论是绝对增大还是相对于身高增大。早期开始治疗时,甲状腺激素治疗可使头围生长恢复正常,而晚期开始治疗时则会使头围进一步增大。身高、骨龄和体重出现追赶生长;然而,只有在1岁前接受治疗的儿童中才会完全恢复正常。

相似文献

1
Head circumference, height, bone age and weight in 103 children with congenital hypothyroidism before and during thyroid hormone replacement.103例先天性甲状腺功能减退症患儿在甲状腺激素替代治疗前及治疗期间的头围、身高、骨龄和体重。
Helv Paediatr Acta. 1985 Sep;40(4):305-16.
2
Head circumference and linear growth during the first 3 years in treated congenital hypothyroidism in relation to aetiology and initial biochemical severity.先天性甲状腺功能减退症治疗后前3年的头围和线性生长与病因及初始生化严重程度的关系
Clin Endocrinol (Oxf). 2004 Jul;61(1):155-9. doi: 10.1111/j.1365-2265.2004.02087.x.
3
Head circumference and body proportions before and during growth hormone treatment in short children who were born small for gestational age.小于胎龄儿出生的矮小儿童在生长激素治疗前及治疗期间的头围和身体比例
Pediatrics. 2004 Sep;114(3):683-90. doi: 10.1542/peds.2003-0152-L.
4
Height prognosis in children with late-diagnosed congenital hypothyroidism.迟发性先天性甲状腺功能减退症患儿的身高预后
Turk J Pediatr. 2001 Oct-Dec;43(4):303-6.
5
IGF-1 and IGFBP in congenital and acquired hypothyroidism after long-term replacement treatment.长期替代治疗后先天性和获得性甲状腺功能减退症中的胰岛素样生长因子-1(IGF-1)和胰岛素样生长因子结合蛋白(IGFBP)
Minerva Endocrinol. 1999 Jun;24(2):51-5.
6
GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial.生长激素治疗及其对小于胎龄儿出生的矮小儿童骨密度、骨成熟和生长的影响:一项随机对照生长激素试验的3年结果
Clin Endocrinol (Oxf). 2003 Dec;59(6):779-87. doi: 10.1046/j.1365-2265.2003.01905.x.
7
IGF-1 and IGFBP-3 in congenital and acquired hypothyroidism after long-term replacement treatment.长期替代治疗后先天性和获得性甲状腺功能减退症中的胰岛素样生长因子-1和胰岛素样生长因子结合蛋白-3
Panminerva Med. 1998 Jun;40(2):103-6.
8
NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).柳氮磺胺吡啶(CAS编号:599-79-1)在F344/N大鼠和B6C3F1小鼠中的NTP毒理学与致癌性研究(灌胃研究)
Natl Toxicol Program Tech Rep Ser. 1997 May;457:1-327.
9
[Accuracy of the methods for height prediction in patients treated for congenital primary hypothyroidism].[先天性原发性甲状腺功能减退症治疗患者身高预测方法的准确性]
An Esp Pediatr. 1997 Dec;47(6):595-600.
10
Recombinant human growth hormone in short children born small for gestational age. German Study Group.重组人生长激素用于小于胎龄儿出生的矮小儿童。德国研究小组。
J Pediatr Endocrinol Metab. 1997 May-Jun;10(3):275-82.

引用本文的文献

1
Incidence of primary congenital hypothyroidism over 24 years in Finland.芬兰 24 年原发性先天性甲状腺功能减退症的发病率。
Pediatr Res. 2023 Feb;93(3):649-653. doi: 10.1038/s41390-022-02118-4. Epub 2022 Jun 3.
2
Risk factors for transient and permanent congenital hypothyroidism: a population-based case-control study.暂时性和永久性先天性甲状腺功能减退症的危险因素:一项基于人群的病例对照研究。
Thyroid Res. 2021 May 5;14(1):11. doi: 10.1186/s13044-021-00103-3.
3
IGSF1 Deficiency: Lessons From an Extensive Case Series and Recommendations for Clinical Management.
IGSF1缺乏症:来自大量病例系列的经验教训及临床管理建议。
J Clin Endocrinol Metab. 2016 Apr;101(4):1627-36. doi: 10.1210/jc.2015-3880. Epub 2016 Feb 3.
4
Association of prenatal perchlorate, thiocyanate, and nitrate exposure with neonatal size and gestational age.产前高氯酸盐、硫氰酸盐和硝酸盐暴露与新生儿大小及胎龄的关联。
Reprod Toxicol. 2015 Nov;57:183-9. doi: 10.1016/j.reprotox.2015.07.069. Epub 2015 Jul 10.
5
European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism.欧洲儿科内分泌学会关于先天性甲状腺功能减退症筛查、诊断和管理的共识指南。
J Clin Endocrinol Metab. 2014 Feb;99(2):363-84. doi: 10.1210/jc.2013-1891. Epub 2014 Jan 21.
6
Growth and specialized growth charts of children with congenital hypothyroidism detected by neonatal screening in isfahan, iran.伊朗伊斯法罕通过新生儿筛查发现的先天性甲状腺功能减退症患儿的生长及特殊生长曲线
ISRN Endocrinol. 2013;2013:463939. doi: 10.1155/2013/463939. Epub 2013 Feb 7.
7
Effect of prolonged discontinuation of L-thyroxine replacement in a child with congenital hypothyroidism.先天性甲状腺功能减退症患儿长期停用左甲状腺素替代治疗的影响。
Case Rep Endocrinol. 2012;2012:841947. doi: 10.1155/2012/841947. Epub 2012 May 8.
8
Congenital hypothyroidism: auxological retrospective study during the first six years of age.
J Endocrinol Invest. 1996 Apr;19(4):224-9. doi: 10.1007/BF03349872.
9
Catch-up growth after prolonged hypothyroidism.长期甲状腺功能减退后的追赶性生长。
Eur J Pediatr. 1996 May;155(5):362-7. doi: 10.1007/BF01955262.
10
Growth in early treated congenital hypothyroidism.早期治疗的先天性甲状腺功能减退症的生长情况。
Arch Dis Child. 1994 Jun;70(6):464-8. doi: 10.1136/adc.70.6.464.